Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03976843 · ClinicalTrials.gov registry record · Phase 2

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
175
Enrollment target
6
Study locations

NCT03976843: Active Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).

NCT03976843 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 175 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03976843, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
175 participants
Enrollment target
6
Study locations

Study Summary

Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate but is at risk of having spread Design: Participants will be screened with: * Medical history * Blood tests * CT and MRI scans: Participants will lie in a machine. The machine will take pictures of the body. * Bone scan Participants will have a radiotracer injected into a vein. They will have a PET/CT scan of their whole body 60-90 minutes later. During the scan, they will lie on their back and stay still. Within 60 days after the scan, participants will have surgery. This will remove the prostate gland and lymph nodes around it. Some tissue will be used for genetic testing. If the PET/CT scan suggests the cancer has spread, participants may need to have another biopsy within 60 days after the scan. After surgery, participants will have follow-up visits for 5 years. They will have 5 visits the first year and 2 the second. Then they will have visits once a year. If participants cancer returns, they will have repeat PET/CT scans.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG 18F-DCFPyL

Study Locations (6)

Maryland

  • Johns Hopkins University - Baltimore
  • National Institutes of Health Clinical Center - Bethesda

Louisiana

  • Tulane University - New Orleans

Massachusetts

  • Brigham and Women s Hospital - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2019-12-04
Est. Completion 2027-11-19
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03976843

The ClinicalTrials.gov registry entry for NCT03976843 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-DCFPyL is the first listed.

NCT03976843 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Louisiana, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03976843 about?

NCT03976843 is a clinical study titled "Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer". Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the ...

What is the current status of trial NCT03976843?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2019-12-04. Estimated completion is 2027-11-19.

What conditions does trial NCT03976843 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03976843?

The interventions under investigation include: 18F-DCFPyL (DRUG).

Who is sponsoring clinical trial NCT03976843?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03976843 being conducted?

This trial has 6 study locations across Louisiana, Maryland, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Louisiana

All trials with a study site in Louisiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.